Intellectual Property
Intellectual Property
Ractigen possesses a prominent IP position in RNAa and oligonucleotide delivery. At Ractigen’s core resides a powerful, high-throughput discovery engine allowing for the rapid identification of saRNAs. Our portfolio is built on composition of matter and methods of use for a growing library of therapeutic oligonucleotides. Medicinal chemistries and delivery platforms developed exclusively in-house further strength our IP estate and empower drug development.
High-Throughput
Process
Our Discovery Engine
It features a highly-refined bioinformatics algorithm integrating epigenetic datasets, design rules, and genome-wide on-target prediction tethered to in-house oligonucleotide manufacturing for saRNA synthesis followed by automated experimental validation of saRNA activity.
Target Gene Locus
Rapidly identify all saRNAs for any single target gene
Search Algorithm
Highly-refined
bioinformatics algorithm
In-House Synthesis
Oligonucleotide manufacturing for in-house saRNA synthesis
In vitro Screening & Gene Expression
Automated rounds of dose-dependent gene expression
3-4 Weeks Start to Finish (All In-House)
Screen Hundreds of saRNA Candidates
Automated rounds of dose-dependent gene expression analytics and integrated de-risking safety assays allow for the screening of hundreds of saRNA candidates within 30-45 days.
Honing the Process
We are continually honing the process in pursuit of full-automation and continue to add to our ever-growing list of therapeutic genes expanding our IP estate and feeding our drug development pipeline.
Want to Discover More?
Check out our News. Below are some highlights to get you started.
Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS
Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s proprietary CNS delivery platform enabling new oligonucleotides therapeutics in the CNS JIANGSU, CHINA…
Read More
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA modality for the treatment of…
Read More
Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform
Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital,…
Read More
Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital
Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (￥110 million) Series A financing round led by Hillhouse Venture Capital…
Read More
